CAS: 54660-78-5; 4-Chloropyrimidin-5-Amine

相似化合物

5413-85-4 5177-27-5 20090-59-9

上下游产品

H-pyrimidine-4-thione5-amino-6-chloro-3H-pyrimidine-4-thione 4-chloro-5-amino-6-mercaptopyrimidine H-pyrimidine-4-thione5-amino-3H-pyrimidine-4-thione 4-chloro-N-(4-chloro-5-pyrimidinyl)-3-cyanobenzamide 2-(4-chloropyrimidin-5-yl)isoindoline-1,3-dione 4-chloro-N-methylpyrimidine-5-amine

5-Amino-6-Chloropyrimidin-4(1H)-Thione Hydrochloride置于氨体系中,用 甲醇 作为反应溶剂,以9.9%的收率获得产物5-氨基-4-氯嘧啶
参考文献:一种激酶抑制剂及其制备和应用
标题:一种激酶抑制剂及其制备和应用
摘要:本发明提供式(I)化合物,或其立体异构体,互变异构体,氮氧化物,代谢物,前药,药学上可接受的盐或溶剂合物,其在制备治疗由pim激酶介导疾病的药物或药物组合物中的应用.

专利信息

专利号:US-10131638-B1
优先权日:2018-03-12
标 题:Synthesis of AZO intermediate
发明人：CARUANA PATRICK A; STERN ALFRED G; ZAITA ALEX J; VO THAO
权利人:US NAVY
摘要:A synthesis for an azo intermediate, 5,5′-azobis(4-chloropyrimidine) is disclosed. 5,5′-azobis(4-chloropyrimidine) is a relatively stable azo compound in that decomposition does not occur until about 194° C. 5,5′-azobis(4-chloropyrimidine) is a product of oxidative dimerization of 5-amino-4-pyrimidine, which a water soluble compound. The azo intermediate is formed in an aqueous solution, but the azo intermediate is substantially insoluble in water; and as it forms it separates producing a reaction mixture that is a slurry. The azo intermediate is isolated by filtration. The azo intermediate is marginally soluble in acetone. The yield is at least 18%, and the oxidizing agent (bleach) is inexpensive, reaction conditions do not require extreme heat or cold, which taken together make the azo intermediate suitable for scaling up.

专利号:US-2002040032-A1
优先权日:2000-07-07
标 题:Methods for stimulation of synthesis of synaptophysin in the central nervous system
发明人：GLASKY MICHELLE S; LAHIRI DEBOMOY K; FARLOW MARTIN R
摘要:A method of increasing the synthesis and/or secretion of synaptophysin comprises administering to a patient with a neurological disease or a patient at risk of developing a neurological disease an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The neurological disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compound can pass through the blood-brain barrier. The purine moiety can be hypoxanthine or guanine. A particularly preferred purine derivative is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl) propanamide.

专利号:US-2004116453-A1
优先权日:2001-07-17
标 题 :Synthesis and methods of use pyrimidine analogues and derivatives
发明人：FICK DAVID B; FOREMAN MARK M; GLASKY ALVIN J
摘要:A pyrimidine derivative or analogue comprises an amino-substituted six-membered heterocyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y 1 )-D, where Y 1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption, or promotes blood-brain barrier penetration of the derivative or analogue. The moiety A can have two or three nitrogen atoms in the ring; typically, the moiety A is a pyrimidine moiety, with two nitrogen atoms in the ring. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.

专利号:WO-0204451-A2
优先权日:2000-07-07
标 题:Methods for stimulation of synthesis of synaptophysin in the central nervous system

专利号:US-2003055249-A1
优先权日:2001-07-17
标 题:Synthesis and methods of use of pyrimidine analogues and derivatives